Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Novel CD20 monoclonal antibodies for lymphoma therapyA phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Expression levels of TWIST1 are associated with the clinicopathological stage of B-cell non-Hodgkin lymphoma.Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsEfficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphomaSiglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.Antibody therapy of pediatric B-cell lymphomaTarget Therapy in Hematological Malignances: New Monoclonal Antibodies.Linked-in: design and efficacy of antibody drug conjugates in oncologyInitial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.Emerging antibody-drug conjugates for treating lymphoid malignancies.Breakthrough therapies in B-cell non-Hodgkin lymphoma.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.DropArray™, a wall-less 96-well plate for uptake and immunofluorescence microscopy, confirms CD22 recycles.Rituximab for the treatment of follicular lymphoma.Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.Novel therapies for aggressive B-cell lymphomaAntibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
P2860
Q24597424-49F89895-6AE4-4C97-8957-90859A84604FQ28390112-C111BD9E-679D-4B45-AC27-4DC0C55D6275Q33431680-BD132A5A-738F-4D31-AF5A-55C1EE827F96Q34292362-A345D1A2-8F5D-44A9-BF9A-681E31315653Q35446333-FC055EE6-A2C8-4641-A881-DAC416A82D57Q36273796-BE3B678F-6CF2-45DB-8E86-C06DAC17AFFBQ36476080-D394A2C9-280E-457A-B7D6-3FA5D022E0F5Q36655884-D6AE9D96-CB2C-43D4-BEBA-58D0C0B87CC7Q36732959-761DB48C-FD61-4DEE-90A3-2A4F3A121A5FQ36979140-E4C48C36-970E-4F65-9610-BBB89D47BEC3Q37029370-31DD0791-AE0E-4145-80C3-C074E7D098CEQ37296134-203C1E58-A9E1-4C34-BDB5-D709686376A7Q38068494-EC70BC36-554D-4718-B298-E336BBA5BFCBQ38202691-79933F03-3A64-4E10-94AC-72D2C67865CAQ38204975-54270E7F-B1D7-4B41-B93D-88DB6EFE6400Q38379829-3AF0E17A-DDDA-40D1-840B-CB315D04CF36Q38550992-42B7198F-6CB9-4D72-BBE0-1E3FACF57201Q38577849-64792150-E09D-4F40-AAFD-32F3192CAE74Q38632313-E47A9914-0DF8-4B9A-8EB9-1CA9F9162C41Q38708600-44E2118D-27EE-4EFA-A7D8-AC501B3991F5Q38932868-A49898AF-E846-4A66-86FA-C7C0CF1C5F20Q38984055-A5B3A035-6779-4BFC-AFB2-4348540B42D5Q39044402-C3A43EE0-1115-4F58-A957-04495F50F0BEQ39360775-28C8E383-3A24-490F-AF49-DDB79E62CA2AQ41674989-CC43028C-77F8-47FA-87E2-A1F69CDA55ADQ42011578-6539BB49-52D6-41B5-9A94-C832DC0D0E8BQ46209550-35D91741-F98A-44C5-991E-7DD6138958B5Q48175954-608AFEBE-9797-4878-A020-A04862AE1C7DQ55205941-E93F46F1-6166-49C7-996E-3DC089E7B7E5
P2860
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.
@ast
Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.
@en
type
label
Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.
@ast
Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.
@en
prefLabel
Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.
@ast
Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.
@en
P2093
P2860
P1433
P1476
Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.
@en
P2093
Erik Vandendries
Kensei Tobinai
Kiyohiko Hatake
Kiyoshi Ando
Kota Tokushige
Michinori Ogura
Taro Ishibashi
P2860
P304
P356
10.1111/J.1349-7006.2012.02241.X
P577
2012-03-20T00:00:00Z